Truffle Capital
Finance · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5 Rue De La Baume, Paris, Ile-de-France,...Phone Number
+33 182284600Website
www.truffle.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Truffle Capital
Truffle Capital is a leading independent European Business Builder that has been financing innovation and supporting pioneering technologies in the fields of BioMedTech and Fintech for over 20 years. The company focuses on creating and developing companies that aim to become tomorrow's leaders in these sectors, with a strong emphasis on addressing unmet medical needs and fostering radical innovation. With a portfolio of 28 active companies and a track record of over 46 successful exits, Truffle Capital partners with world-class entrepreneurs to build category-defining leaders. The firm is led by co-founders Philippe Pouletty, M.D. and Bernard-Louis Roques, and has raised more than 1.2 billion euros since its inception.Explore more
Truffle Capital Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Truffle Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Truffle Capital had a recent Job posting/layoffs
Truffle Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Truffle Capital is spiking on competitors!
Product Launch: Get notified when Truffle Capital launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Truffle Capital has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Truffle Capital recently announced quarterly report
Funding: Get notified immidiatlly once Truffle Capital has new funding data
Congratulate Masked Content for being promoted to Masked Content at Truffle Capital
Recommended Actions
Reach out to Masked Content who joined Truffle Capital as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Truffle Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Truffle Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Truffle Capital.
Truffle Capital financials insights
Gather financial insights about Truffle Capital, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$322.6M
Truffle Capital Tech Stack
A closer look at the technologies used by Truffle Capital
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Truffle Capital News & Media
SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients
PARIS--(BUSINESS WIRE)--SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABSpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients
PARIS--(BUSINESS WIRE)--SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and license option agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMABK lLevenue Acquires Cake; Raises €8M in Series A Funding
Levenue, a Breda, the Netherlands-based revenue-based investing marketplace, raised €8M in Series A funding. The round was led by Truffle Capital with participation from Freshmen Fund. The company, which also acquired Cake, a company known for its open banking and data enrichment technology, intends to use the funds to accelerate its growth as Europe’s revenue-based financing […] The post Levenue Acquires Cake; Raises €8M in Series A Funding appeared first on FinSMEs.
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Truffle Capital
Sign Up For FreeTo access detailed company insights
Truffle Capital is a leading independent European Business Builder that has been financing innovation and supporting pioneering technologies in the fields of BioMedTech and Fintech for over 20 years. The company focuses on creating and developing companies that aim to become tomorrow's leaders in these sectors, with a strong emphasis on addressing... Read More
